SKLB325

Overview

SKLB325 is a Jumonji domain-containing 6 ( JMJD6 ) inhibitor with a binding affinity ( K D ) value of 0.755 μM, and the IC 50 value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis . SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) .

Application

Products | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Histone Demethylase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-139782
• CAS No.: 66680-03-3
• Molecular Formula: C12H12N4O2
• Molecular Weight: 244.25
• Purity: 99.21%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (8.52 mM); Clear solution
• Availability: In-stock

Source

Original product source